2seventy bio, Inc. (TSVT)
(Delayed Data from NSDQ)
$4.29 USD
+0.02 (0.47%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $4.21 -0.08 (-1.86%) 7:22 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Income Statements
Fiscal Year end for 2seventy bio, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 100 | 92 | 55 | 248 | 44 |
Cost Of Goods | 17 | 17 | 3 | 5 | 3 |
Gross Profit | 83 | 75 | 52 | 243 | 41 |
Selling & Adminstrative & Depr. & Amort Expenses | 321 | 338 | 366 | 381 | 382 |
Income After Depreciation & Amortization | -238 | -263 | -314 | -138 | -341 |
Non-Operating Income | 20 | 9 | 22 | 18 | 20 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -218 | -254 | -292 | -120 | -321 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -218 | -254 | -292 | -120 | -321 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -218 | -254 | -292 | -120 | -321 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -215 | -252 | -298 | -125 | -328 |
Depreciation & Amortization (Cash Flow) | 22 | 12 | 16 | 13 | 13 |
Income After Depreciation & Amortization | -238 | -263 | -314 | -138 | -341 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 49.28 | 35.64 | 23.50 | NA | NA |
Diluted EPS Before Non-Recurring Items | -4.00 | -7.13 | -12.44 | NA | NA |
Diluted Net EPS (GAAP) | -4.42 | -7.13 | -12.44 | NA | NA |
Fiscal Year end for 2seventy bio, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 10.68 | 12.03 | 36.05 | 41.62 |
Cost Of Goods | NA | 3.15 | 4.96 | 4.52 | 4.30 |
Gross Profit | NA | 7.54 | 7.08 | 31.53 | 37.33 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 67.48 | 85.05 | 79.52 | 89.04 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -59.94 | -77.97 | -47.99 | -51.71 |
Non-Operating Income | NA | 3.11 | 6.33 | 5.90 | 4.69 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -56.82 | -71.64 | -42.09 | -47.02 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -56.82 | -71.64 | -42.09 | -47.02 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -56.82 | -71.64 | -42.09 | -47.02 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 51.38 | 51.18 | 50.97 | 43.47 |
Diluted EPS Before Non-Recurring Items | NA | -1.11 | -1.00 | -0.83 | -1.08 |
Diluted Net EPS (GAAP) | NA | -1.11 | -1.40 | -0.83 | -1.08 |